Insider Brief
- Proscia expects its AI pathology platform, Concentriq, to support diagnoses for 32,000 patients daily—a 400% year-over-year increase—as adoption accelerates across major laboratories.
- The company has introduced five pre-configured AI application suites for cancer detection, biomarker analysis, and quality control to streamline integration and standardize diagnostics.
- Proscia has expanded support services and integrated Concentriq with over 100 laboratory systems while enabling new lab revenue through pharmaceutical partnerships and real-world data licensing.
Proscia, a Philadelphia-based software company focused on digitizing pathology through artificial intelligence, is poised to quadruple daily usage of its platform, with 32,000 patients expected to be diagnosed each day using its Concentriq software—marking a 400% increase over the previous year.
The milestone reflects the company’s accelerating push into routine diagnostics, driven by broader adoption from clinical laboratories seeking to streamline operations and integrate AI into high-volume medical workflows. According to a company statement, Proscia’s growth is being fueled by demand for scalable AI tools that improve diagnostic consistency and efficiency, while opening new commercial opportunities for labs.
Founded to modernize the traditionally analog field of pathology, Proscia has emerged as a major player in the push to digitize diagnostic processes using whole-slide imaging and machine learning. The company’s platform, Concentriq, now serves as the digital backbone for a global network of labs that increasingly rely on automated systems to help pathologists detect and score cancers, assess tissue quality and guide treatment decisions.
“Our success with digital pathology has depended on Proscia’s world-class technology, along with its mission, vision, and collaborative culture,” said Bilal R. Ahmad, MD, MBA, Hematopathologist at Spectrum Healthcare Partners, said in the statement. “From day one, Proscia has treated us as a true partner. That commitment has enabled us to build a program that continues to deliver impact at scale.”
Pre-Packaged AI Application Suites Target Key Disease Areas
A central element of Proscia’s latest growth spurt is the launch of five application suites designed to accelerate AI adoption for high-impact medical cases. These new offerings, pre-configured and integrated directly into the Concentriq platform, are tailored for diseases where accuracy, speed, and standardized reporting are critical.
The suites include tools for breast and prostate cancer detection, quantitative biomarker scoring, automated Gleason grading, and metastasis prediction. Other modules assist in evaluating gastric conditions such as H. pylori and chronic gastritis, and a separate prognostic suite provides risk stratification for colon and breast cancers. A quality control suite helps labs assess stain quality and identify image artifacts across more than ten indications.
By bundling these capabilities into cohesive packages, Proscia aims to reduce the friction of adopting tools from multiple vendors and improve interoperability across diagnostic systems. The move supports labs seeking to improve diagnostic output while maintaining clinical guidelines and reporting standards.
Around-the-Clock Support Enhances Platform Usability
As more labs adopt Proscia’s cloud-based Concentriq platform, the company has responded with enhanced customer service options, including 24/7 technical support. This premium service tier is managed by Proscia’s customer experience team and is tailored for organizations aiming to scale to full digital pathology adoption.
The company says the expanded support function reflects its focus on being a long-term operational partner rather than a vendor, especially for labs in transition from analog to digital workflows. In a recent third-party survey conducted by KLAS Research, Proscia received top ratings across customer satisfaction metrics, including an ‘A+’ for web and phone support, and unanimous agreement from customers that they would repurchase and continue the partnership.
Deeper Integration with Laboratory Information Systems
A key pillar of Concentriq’s utility lies in its compatibility with over 100 laboratory information systems (LIS), including widely used platforms like CoPath, Epic Beaker, NovoPath, LigoLab, and Orchard Harvest. These integrations allow data to flow between pathology imaging tools and core lab databases, ensuring that AI-assisted diagnostics are synchronized with hospital records and clinical workflows.
Proscia’s integrations use bidirectional HL7 interfaces, a messaging standard in healthcare that enables consistent data sharing across systems. This capability allows pathologists to access AI-generated insights within their normal review process and helps laboratories maintain throughput and consistency while reducing turnaround times.
The company frames this interoperability as essential for labs that are already operating at capacity and need ways to both improve performance and reduce operational complexity. Tight LIS integration also lays the foundation for broader AI deployment in regulated clinical environments, where traceability and auditability are required.
Revenue Expansion Through Diagnostic Network
Proscia’s ambitions go beyond digitizing diagnostics. The company is also building new economic models for clinical labs. Since launching its diagnostic network in 2024, the company has helped participating laboratories generate new revenue by tapping into real-world data partnerships and pharmaceutical services.
The network aggregates over 12 million whole-slide images, along with pathology reports, molecular test results, and genomic data from more than 2 million patients. This dataset is made available to biopharmaceutical companies for licensing, supporting research into biomarkers, drug development, and precision diagnostics.
Labs in the network can also serve as live testbeds for validating new AI applications. This creates real-world evidence needed by technology vendors and drug companies to support regulatory submissions or refine models before commercial rollout. In addition, participating labs can offer services such as clinical trial support and companion diagnostic development, using Proscia’s digital tools as a delivery platform.
These initiatives allow laboratories to move beyond fee-for-service diagnostics into higher-margin segments that blend clinical care with life sciences research.
Strategic Backing and Market Position
Proscia’s growth has been underwritten by Insight Partners, a software-focused investment firm with more than $90 billion in assets under management. The backing has enabled the company to expand its product suite, build global partnerships, and develop enterprise-scale support infrastructure, all aimed at establishing Concentriq as a foundational platform in digital pathology.
The company operates in a fast-evolving market where AI is increasingly embedded into medical workflows, and where scale and interoperability are seen as prerequisites for clinical adoption. As health systems worldwide face mounting diagnostic demands and staffing shortages, Proscia is positioning its platform as a way to deliver consistent, data-driven diagnoses without overburdening existing teams.
While the clinical use of AI remains subject to regulatory oversight and ongoing validation, Proscia’s strategy appears designed to mitigate adoption hurdles by embedding AI tools within broader software ecosystems already used by labs.
“For years, AI-driven pathology has promised to deliver top- and bottom-line impact for diagnostic laboratories, but that potential has largely been confined to efficiency gains and increased volume,” said Tom Gallo, Proscia’s Chief Financial Officer, in the statement. “Through our diagnostic network, laboratories are not only recouping the cost of going digital but also unlocking high-margin revenue opportunities reshaping their economics.”
